After last year’s ESMO meeting in Munich, the recent ESMO Congress in Barcelona again proved to be a ‘grand cru’ in gynaecological cancer, with the confirmation of the role of maintenance therapy with PARP inhibitors in first-line therapy of advanced ovarian cancer, even beyond BRCA mutation. Additionally, recent progress in the management of endometrial and cervical cancer will be highlighted in this overview.